Immunological and other laboratory studies of patients receiving short-term cimetidine therapy.
D000284:Administration, Oral; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001500:BCG Vaccine; D002464:Cell Migration Inhibition; D004406:Dysgammaglobulinemia / Q000139:chemically induced; D005260:Female; D006146:Guanidines / Q000008:administration & dosage / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007111:Immunity, Cellular / Q000187:drug effects; D007070:Immunoglobulin A; D007962:Leukocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009163:Mycobacterium bovis; D010437:Peptic Ulcer / Q000188:drug therapy; D013997:Time Factors
D001500:BCG Vaccine; D006146:Guanidines; D006635:Histamine H2 Antagonists; D007093:Imidazoles; D007070:Immunoglobulin A; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase